Oxford biotech startup Nightstar Therapeutics plans US NASDAQ float

OCTOBER 20-21st | SALT LAKE CITY, UT

Founded in 2014, the company has developed a technology that could cure blindness.

Nightstar is the latest in a number of UK-based healthcare companies looking to US markets for IPOs. Investors in the US are said to have a better understanding of biotech, which leads them to value early-stage companies at higher amounts.

Nightstar is set to float at an estimated valuation of $250m.

The firm has raised funds through three rounds of investment, the most recent of which raised $45m in June.

The London Stock Exchange has not lost out on all recent floats in the sector, however. Last month, biotech company Destiny Pharma said it was plotting a London float.

Source: Oxford biotech startup Nightstar Therapeutics plans US float | City A.M.

%d bloggers like this: